(Total Views: 721)
Posted On: 05/25/2020 5:40:54 AM
Post# of 145900
Itolizumab is a CD6 receptor inhibitor. IL-17 is the proinflammatory chemokine associated with CD6 but is fairly weak compared to IL-6. Itolizumab would reduce inflammation but I wouldn't expect an overwhelming response.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)